Medicare Part D covers Ozempic (semaglutide) when prescribed for type 2 diabetes management. However, Medicare does NOT cover Ozempic or other GLP-1 drugs when prescribed solely for weight loss — this remains a significant coverage gap as of 2024.
Ozempic for Diabetes: Covered
Ozempic is FDA-approved for type 2 diabetes and is covered under Medicare Part D plans that include it on their formulary. Your cost depends on your plan’s tier structure—Ozempic is typically a Tier 3 or Tier 4 medication with higher cost-sharing.
Wegovy for Weight Loss: Not Covered (Yet)
Wegovy is the same drug (semaglutide) at a higher dose, approved specifically for chronic weight management. Original Medicare and most Part D plans do not cover Wegovy because Congress has not yet authorized Medicare coverage of weight loss drugs. Some Medicare Advantage plans have begun adding obesity drug coverage, but this is still uncommon.
Mounjaro, Zepbound, and Other GLP-1 Drugs
- Mounjaro (tirzepatide) — covered by Part D when prescribed for type 2 diabetes
- Zepbound (tirzepatide)—same drug as Mounjaro but at obesity-approved dosage; not covered for weight loss only
- Rybelsus (oral semaglutide) — covered for type 2 diabetes under Part D
Potential Future Coverage
There is active legislative discussion about adding obesity drug coverage to Medicare. The Treat and Reduce Obesity Act (TROA) has been introduced in Congress multiple times. As GLP-1 drugs become more widely recognized as medical treatments for obesity, coverage is expected to expand—follow Medicare.gov for updates.
Reducing Your Ozempic Costs
- Manufacturer savings programs (NovoCare) may reduce out-of-pocket costs
- Compare Part D plans annually at Medicare.gov—formularies and costs differ
- Extra Help (LIS) program reduces drug costs for low-income beneficiaries
